Data from two studies suggest that a once-daily combination therapy of doravirine and islatravir was noninferior to current, ...

Switching to islatravir and doravirine was just as effective as bictegravir/emtricitabine/tenofovir alafenamide fumarate (BIC ...

MSD’s HIV treatment is now back on track after an earlier hit which saw the FDA place a clinical hold on the therapy.

The development of new classes of antiretroviral drugs, such as integrase inhibitors and CCR5-antagonistic entry inhibitors, has opened the possibility of considering regimens without NRTIs (Table 1).

Nucleoside reverse transcriptase inhibitors (NRTIs), and nucleotide reverse transcriptase inhibitors (NtRTIs), often all referred to as NRTIs, work by targeting the action of an HIV protein called ...

Efavirenz (EFV), brand-named drugs such as Sustiva, is an antiretroviral drug utilized mostly for HIV/AIDS treatment and prevention. Efavirenz is a category of drugs that fall under non-nucleoside ...

[2] Tenofovir was approved by the Food and Drug Administration (FDA) in October 2001 through an accelerated approval process; it is the first nucleotide analogue reverse-transcriptase inhibitor ...

Cosalane is undergoing preclinical development. Also has developed a new reverse transcriptase inhibitor called "ADAM," and analogs of it are being created and evaluated as HIV-1 reverse transcriptase ...

Efavirenz (EFV), sold under the brand names Sustiva among others, is an antiretroviral medication used to treat and prevent HIV/AIDS.

To test whether targeting transposable elements could help treat cancer, Gudkov, Greenbaum, and others have examined the effect of giving cancer cells a so-called reverse transcriptase inhibitor that ...

Gilead Sciences announced a significant milestone: the U.S. FDA accepted their New Drug Applications (NDAs) for lenacapavir ...